SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SIGA Technologies reports strong revenue diversification and growth opportunities

SIGA Technologies delivered robust financial results in 2022, showcasing revenue diversification and positive cash flows. With a focus on TPOXX and upcoming FDA submissions, the company is poised for growth. Challenges lie in regulatory hurdles and operational complexities, but opportunities abound in US Government procurement and international sales expansion.

SIGA Technologies projects robust 2023 performance with strategic growth initiatives

SIGA Technologies is poised for a successful 2023, driven by strong financial expectations and product delivery targets. The company's focus on innovation, strategic partnerships, and market expansion positions it well for future growth. Challenges in negotiations, clinical trials, and program scalability require careful management to capitalize on emerging opportunities.

SIGA Technologies projects robust growth in 2023 amidst operational challenges

SIGA Technologies is poised for strong financial performance in the second half of 2023, with revenue expectations and operating income growth.
The company's focus on TPOXX as a key treatment for orthopoxviruses and international sales growth positions it well for future success.
While facing challenges in trial data analysis and CEO transition, SIGA has opportunities for market expansion and revenue diversification.

SIGA Technologies reports solid Q3 earnings amidst packaging challenges

SIGA Technologies is navigating packaging delays and inventory build-up while maintaining a strong financial position. Promising programs and trials indicate growth potential, with opportunities for additional orders and upsells in the EU market.

SIGA Technologies excels in Q4 2023 earnings, eyes innovation and growth

SIGA Technologies delivered impressive financial results in Q4 2023, with strong revenue growth and profitability. Despite facing challenges in contract extensions and manufacturing capacity, the company remains focused on innovation and expansion to drive future growth and value creation.

SIGA Technologies excels in Q1 2024, navigates health challenges

SIGA Technologies delivered a strong performance in Q1 2024, marked by revenue growth, operational efficiency, and strategic advancements. While maintaining a solid financial position, the company faces challenges related to public health concerns and regulatory complexities. Leveraging opportunities in product expansion and global partnerships will be key to sustaining growth and market leadership.

SIGA Technologies reports robust Q2 earnings and global expansion plans

SIGA Technologies' Q2 2024 performance reflects strong revenue growth and financial stability.
The company's focus on diversification, international expansion, and innovation positions it for future success.
Challenges in government contract negotiations and regulatory approvals are balanced by growth opportunities and positive outlook.

SIGA Technologies reports robust Q3 earnings and eyes global expansion

SIGA Technologies' Q3 2024 earnings call reflects strong financial performance, strategic partnerships, and a focus on innovation and market expansion.
The company's commitment to product safety, efficacy, and diverse revenue sources positions it well for future growth and sustained profitability.
While facing challenges in regulatory approvals and market competition, SIGA's financial stability, product credibility, and growth opportunities present a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SIGA made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 14, 2023.

Best Value Stocks to Buy for April 14th

Liberty Oilfield Services

RenaissanceRe Hlds

Urban Outfitters

Count on value stocks like RNR, URBN, LBRT and SIGA displaying high earnings yield to tide over the current economic uncertainty.

4 High Earnings Yield Value Picks Amid Prevailing Uncertainty

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Phil Gomez - Chief Executive Officer Dan Luckshire - Chief Financial Officer Conference Call Participants Soo Romanoff - Edison Group Operator Ladies and gentlemen, greetings and welcome to the SIGA Technologies Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants' lines are in a listen-only mode.

SIGA Technologies, Inc. (SIGA) Q4 2022 Earnings Call Transcript

- Approximately $71 Million of International Product Sales in 2022 -

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022

NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 2nd, 2023. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results

SIGA Board of Directors has initiated search for new CEO; Dr. Gomez expected to remain in position as CEO until the search is completed to support the transition to a new CEO in 2023 SIGA Board of Directors has initiated search for new CEO; Dr. Gomez expected to remain in position as CEO until the search is completed to support the transition to a new CEO in 2023

SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Phil Gomez - CEO Dan Luckshire - CFO Conference Call Participants Ken Mestemacher - Edison Brian Adams - Carter, Terry & Company Operator Welcome to the SIGA business update call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations, and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

SIGA Technologies, Inc. (SIGA) Q3 2022 Earnings Call Transcript

- Approximately $61 Million of International Sales in the Third Quarter –

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 3rd, 2022. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results

NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox.

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

The company has only one product: a monkeypox vaccine.

Why SIGA Technologies Stock Fell 31.7% in September

It's a great day to be invested in Siga Technologies (NASDAQ: SIGA ) stock — or at least, it ought to be. The markets can be mysterious sometimes, though.

SIGA Stock Alert: Siga Technologies Receives $11 Million Order for Monkeypox Drug

- In 2022, the U.S. Department of Defense has Awarded Procurement Contracts for the Purchase of up to $18.1 Million of Oral TPOXX – - In 2022, the U.S. Department of Defense has Awarded Procurement Contracts for the Purchase of up to $18.1 Million of Oral TPOXX –

SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®

- Order for Approximately $10 Million Funded by the European Commission –

SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)

AbbVie

ADMA Biologics

Geron

Prometheus Biosciences

Voyager Therapeutics

Axsome Therapeutics

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

7 Top-Rated Biotech Stocks to Buy for Q4

Quest Diagnostics

One sells a treatment. The other sells a diagnostic test.

Better Monkeypox Stock: SIGA Technologies vs. Quest Diagnostics

The stock has been crashing in recent weeks.

Is the Bubble Bursting for SIGA Technologies?

Palantir Technologies

For those unfamiliar with the term, a meme stock is a stock that has seen an increase in price due to attention on social media platforms like Reddit. In recent months, we've seen meme stocks like GameStop (NYSE: GME ) and AMC Entertainment (NYSE: AMC ) skyrocket in value, much to the surprise of traditional investors.

3 Picks That Could Be the Next Meme Stock Champion

Rhythm Pharmaceuticals

Veru

These three healthcare stocks have defied the 2022 bear market.

What Bear Market? These 3 Stocks Have Been Rocketing Higher in 2022

Not only is Siga's share price up, but trading volumes are through the roof.

Could This Be the Next Big Meme Stock?

Moderna

Shares of the company have jumped more than 60% in just the past month.

Could SIGA Technologies Become the Next Moderna?

Applied DNA Sciences

Chimerix

Geovax Labs

iShares Genomics Immunology and Healthcare ETF

Tonix Pharmaceuticals Hld

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names.

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

Ayala Pharmaceuticals

Blue Water Vaccines

E-Home Household Service Holdings Ltd

Ameri Holdings

Koss

Stronghold Digital Mining

The beaten-down stock market has created an opportunity for contrarian investors in short-squeeze stocks. Essentially, bearish traders must borrow the underlying securities which they are pessimistic about.

7 Short-Squeeze Stocks to Put on Your Must-Watch List

Tarena International

In a year where investing in stocks was more challenging than usual, finding winning stocks has been tough.

These three stocks recorded gains of over 200% year-to-date

- IV TPOXX is an Important Option for Those Unable to Swallow –

News for SIGA Technologies Stock (SIGA)